CHAPERONE-BASED INTEGRIN INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Nov 27, 2014
app pub date -
May 23, 2014
filing date -
May 23, 2013
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present disclosure provides isolated integrin αL polypeptides, such as α7 helix polypeptides from the alpha I domain of integrin. Such polypeptides inhibit the interaction between integrin and gp96, thereby inhibiting gp96 activity. Such inhibition can be used to prevent cancer cell growth, cancer metastasis and/or inflammation.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully